Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Neville Kukreja , Patrick W Serruys Added: 3 years ago
In 2002–2003, drug-eluting stents (DES) were approved by regulatory bodies in Europe and the USA after initial studies showed a dramatic reduction in rates of restenosis compared with bare metal stents (BMS). Subsequent randomized trials in more challenging lesions have confirmed this benefit with a reduction in restenosis of 60–80%, irrespective of the type of lesion or clinical syndrome… View more

Intervention
Author(s): Gaku Nakazawa , Aloke V Finn , Renu Virmani Added: 3 years ago
Polymer-based sirolimus (Cypher®) and paclitaxel (Taxus®) drug-eluting stents (DES) have reduced rates of restenosis and target lesion revascularization (TLR) compared with bare-metal stents (BMS) and have launched a revolution in the interventional treatment of symptomatic coronary artery disease.1,2 However, this overwhelming enthusiasm has recently been dampened by safety concerns regarding a… View more

Anticoagulation

Intervention
Dual Antiplatelet Therapy After Drug-eluting Stent Implantation
Author(s): Giulia Magnani , Marco Valgimigli Added: 3 years ago
Dual antiplatelet therapy (DAPT), defined as the use of a P2Y12 receptor inhibitor (clopidogrel, ticagrelor or prasugrel) and aspirin, is required after percutaneous coronary intervention (PCI) with drug-eluting stents (DES).1 Although the use of DES has been shown to reduce the rate of restenosis as compared with bare-metal stents (BMS), there is concern that DES may be associated with a higher… View more

Anticoagulation

Prevention & Chronic Conditions
Author(s): Gaku Nakazawa , Masataka Nakano , Marc Vorpahl , et al Added: 3 years ago
The limited information regarding the long-term safety of drug-eluting stents (DES) for the treatment of ST-segment-elevation myocardial infarction (STEMI) has raised concern regarding its clinical safety, in particular with respect to the associated morbidity and mortality attributed to late stent thrombosis (LST). Observational studies in daily practice have shown that the risk of LST continues… View more

MI/ACS

Intervention
Added: 3 years ago
By Liam O'Neil, TCT 2015, San Francisco, USA Results of the ABSORB III Trial presented at Transcatheter Cardiovascular Therapeutics (TCT) 2015 San Francisco showed that an everolimus-eluting bioresorbable vascular scaffold was non-inferior after one year compared to a current generation metallic drug-eluting stent (DES) for target lesion failure in patients with noncomplex obstructive CAD at 1… View more
Added: 3 years ago Source:  BIOTRONIK
BIOTRONIK’s Ultrathin-Strut Drug-Eluting Stent Soon Available in China Following Market Approval BEIJING, China and BUELACH, Switzerland, October 30, 2019 – BIOTRONIK announced today that its Orsiro® coronary drug-eluting stent (DES) has been approved for sale in China by the National Medical Products Administration. The company expects to make the device available to Chinese patients and… View more
Author(s): Robert A Byrne , Eric Eeckhout , Gennaro Sardella , et al Added: 3 years ago
Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are established strategies for revascularisation in patients with coronary artery disease. While CABG was the standard of care for patients with multivessel disease, the introduction of baremetal stents (BMSs) and, later, drug-eluting stents (DESs) has led to an increased use of PCI in these more challenging cases… View more

Prevention & Chronic Conditions

Intervention
Author(s): Carlo Briguori , Antonio Colombo Added: 3 years ago
Patients with type 2 diabetes mellitus represent 25% of those requiring myocardial revascularisation.1 Although current guidelines favour coronary bypass surgery (CABG) over percutaneous coronary intervention (PCI) in most diabetics who require revascularisation, 2–3 substantial variability exists in practice patterns between individual hospitals, suggesting a lack of clinical consensus.4 The… View more

Prevention & Chronic Conditions

Intervention
Added: 3 years ago
Rome, Italy 30 August 2016:New generation drug eluting stents (new DES) did not outshine contemporary bare metal stents (BMS) as they were expected to, in a surprise finding of the largest randomized stent trial to date. The Norwegian Coronary Stent Trial (NorStent), presented at ESC Congress 2016, “demonstrates that the efficacy of new DES versus contemporary BMS is lower than expected,” noted… View more
Author(s): Scott W Murray , Mohammed Andron , Raphael A Perry , et al Added: 3 years ago
In 2002, a 60-year-old man suffered an inferior ST elevation myocardial infarction (STEMI), which was initially successfully treated with thrombolysis. He was then referred to our center for percutaneous coronary intervention (PCI) due to post-infarct angina. In his past history he was a very heavy smoker with an 80-pack-per-year history. He also had established hypertension, a family history of… View more

Intervention